AI
By
Can Ambience Healthcare’s $243M Series C Push the AI Scribing Market Toward a $5B Future?
Key Highlights Record Funding and Unicorn StatusAmbience Healthcare, founded in 2020 in San Francisco, announced a $243 million…
Could Eli Lilly’s $1.3 Billion GPCR Deal with Superluminal Medicines Unlock a New Era in Targeted Therapeutics?
Key Highlights Eli Lilly Taps AI-Powered Drug Discovery in Landmark GPCR Agreement Eli Lilly has entered a global…
How Will Bayer’s $1.3 Billion Bet on KRAS G12D and Novartis’ Triple Phase 3 Wins Transform Cancer and Immune Therapy?
Key Highlights Bayer Targets KRAS G12D Mutation with Landmark Licensing Deal Bayer has entered a global exclusive licensing…
How Google Med-Gemini’s “Basilar Ganglia” AI Hallucination Signal a Wake-Up Call for Safer AI in Medical Diagnostics?
Key Highlights: AI Hallucination: The “Basilar Ganglia” ErrorGoogle’s Med-Gemini suite, designed to summarize health data and generate radiology…
Will Tempus AI’s FDA Clearance Redefine the Future of Cardiac Imaging?
Key Highlights: Tempus AI Secures FDA Clearance for Tempus Pixel Tempus AI announced that its advanced imaging platform,…
Can DeepMind’s Demis Hassabis Slash Drug Discovery Timelines From Years to Months—And What Does That Mean for Pharma Startups?
Key Highlights: What Hassabis Says: A Turning Point for Drug DiscoveryDemis Hassabis, CEO of DeepMind, recently told Bloomberg…
